Screener
Boston Scientific BSX Cardiovascular — Research and development expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Boston Scientific in its filing.
Tagged under the XBRL concept bsx:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostAdjusted.
The source filing: Boston Scientific’s 10-Q, filed May 1, 2026.
- Filed
- May 1, 2026, 6:25 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000885725-26-000033
| (in millions, except percentages) | Med Surg | % of Net Sales | Cardiovascular | % of Net Sales | Total |
|---|---|---|---|---|---|
| Segment expenses: | |||||
| Cost of products sold | 478 | 28.1% | 1,067 | 30.5% | |
| Selling, general and administrative expenses | 557 | 32.8% | 959 | 27.4% | |
| Research and development expenses | 127 | 7.5% | 343 | 9.8% | |
| Other segment items(1) | 5 | 0.3% | 7 | 0.2% | |
| Segment operating income(2) | 533 | 31.3% | 1,125 | 32.1% | 1,658 |
| Unallocated amounts: | |||||
| Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments | (199) |
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Boston Scientific's cardiovascular — research and development expenses?
- Boston Scientific (BSX) reported cardiovascular — research and development expenses of $343M in Q1 2026.
- How has Boston Scientific's cardiovascular — research and development expenses changed year-over-year?
- Boston Scientific's cardiovascular — research and development expenses increased by 21.2% year-over-year, from $283M to $343M.
- What is the long-term trend for Boston Scientific's cardiovascular — research and development expenses?
- Over 3 years (2022 to 2025), Boston Scientific's cardiovascular — research and development expenses has grown at a 18.8% compound annual growth rate (CAGR), from $782M to $1.31B.
- What does cardiovascular — research and development expenses mean?
- Captures the investment in innovation, clinical trials, and product development specifically for the Cardiovascular segment. This is a critical indicator of the segment's future growth potential and pipeline strength.
Ask your AI about Boston Scientific's cardiovascular — research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude